Last $1.93 USD
Change Today +0.07 / 3.76%
Volume 41.4K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

medicinova inc (MNOV) Snapshot

Open
$1.87
Previous Close
$1.86
Day High
$1.93
Day Low
$1.85
52 Week High
01/14/14 - $5.25
52 Week Low
04/15/14 - $1.66
Market Cap
46.5M
Average Volume 10 Days
119.7K
EPS TTM
$-0.52
Shares Outstanding
24.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINOVA INC (MNOV)

Related News

No related news articles were found.

medicinova inc (MNOV) Related Businessweek News

No Related Businessweek News Found

medicinova inc (MNOV) Details

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

11 Employees
Last Reported Date: 03/27/14
Founded in 2000

medicinova inc (MNOV) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2012.

medicinova inc (MNOV) Key Developments

MediciNova Inc. Appoints Yoshio Ishizaka to its Board of Directors

MediciNova Inc. announced the appointment of Mr. Yoshio Ishizaka to its Board of Directors. Mr. Ishizaka complements the MediciNova Board with 50 years of experience in marketing and product development with Toyota Motor Corporation (TMC). His international experience includes assignments in Japan, Europe and the U.S.

Medicinova Inc Appoints Esther van den Boom as Chief Financial Officer

MediciNova Inc. announced the appointment of Esther van den Boom as Chief Financial Officer. Ms. van den Boom is owner of van den Boom & Associates, LLC, an accounting services firm that provides accounting and finance services to public and private companies. Prior to starting van den Boom & Associates, Ms. van den Boom spent nine years with Ernst & Young LLP as a Senior Manager in their audit practice where she assisted public and private biotechnology companies.

MediciNova Inc., 2013 Earnings Call, Mar 28, 2014

MediciNova Inc., 2013 Earnings Call, Mar 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNOV:US $1.93 USD +0.07

MNOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNOV.
View Industry Companies
 

Industry Analysis

MNOV

Industry Average

Valuation MNOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINOVA INC, please visit www.medicinova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.